| P50 | author | Sarah L Sammons | Q87708014 |
| P2093 | author name string | Kimberly L Blackwell | |
| | Donna L Topping | |
| P2860 | cites work | PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro | Q21195212 |
| | Cell cycle, CDKs and cancer: a changing paradigm | Q24314465 |
| | Comprehensive molecular portraits of human breast tumours | Q24630844 |
| | CDK4/6 inhibition in luminal breast cancer | Q26739836 |
| | Targeting CDK4/6 in patients with cancer | Q26750703 |
| | Developments in the management and treatment of pulmonary embolism | Q26795642 |
| | The Cancer Genome Atlas: clinical applications for breast cancer | Q38195619 |
| | Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline | Q38842745 |
| | Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer | Q38846176 |
| | Palbociclib and Letrozole in Advanced Breast Cancer | Q39105459 |
| | Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). | Q39638408 |
| | Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study | Q39660526 |
| | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind | Q39944735 |
| | Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint | Q40020499 |
| | Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. | Q40492303 |
| | Targeting the RB-pathway in cancer therapy | Q42021453 |
| | Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer | Q42723815 |
| | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | Q45044547 |
| | Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors | Q46137197 |
| | Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies | Q46363308 |
| | Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. | Q53068186 |
| | Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. | Q54348570 |
| | Drug-induced liver injury | Q76383956 |
| | Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy | Q79825413 |
| | The cell cycle and cancer | Q85077091 |
| | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study | Q27853110 |
| | Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers | Q28069910 |
| | Cyclin D as a therapeutic target in cancer | Q28242623 |
| | CDK6 as a key regulator of hematopoietic and leukemic stem cell activation | Q28587749 |
| | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). | Q30317064 |
| | Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer | Q30419997 |
| | Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data | Q30989472 |
| | CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment | Q33419302 |
| | A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas | Q33434752 |
| | Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression | Q33603027 |
| | Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. | Q33968055 |
| | Palbociclib: an evidence-based review of its potential in the treatment of breast cancer | Q34027724 |
| | Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways | Q34147910 |
| | Nursing strategies for patients on oral chemotherapy | Q34162889 |
| | Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine | Q34217662 |
| | Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia | Q34403621 |
| | The history and future of targeting cyclin-dependent kinases in cancer therapy | Q34460347 |
| | Management of febrile neutropenia: ESMO Clinical Practice Guidelines | Q34620670 |
| | Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). | Q35034758 |
| | What Clinicians Should Know About the QT Interval | Q35112554 |
| | ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer | Q35479617 |
| | High frequency of aberrant p16(INK4A) expression in human breast cancer | Q35782316 |
| | Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion | Q35810732 |
| | Recommended guidelines for the treatment of cancer treatment-induced diarrhea | Q35836588 |
| | Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea | Q35840388 |
| | Cell cycle control in breast cancer cells | Q36305565 |
| | RB and cell cycle progression | Q36579245 |
| | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. | Q36589865 |
| | Mechanisms of Endocrine Resistance in Breast Cancer | Q36851417 |
| | Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial | Q36914459 |
| | Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. | Q37584898 |
| | Review article: drug-induced liver injury in clinical practice | Q37726069 |
| | Signaling through cyclin D-dependent kinases | Q38104238 |
| | Start and the restriction point | Q38126722 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein kinase inhibitors | Q7251487 |
| | antineoplastic | Q2853144 |
| | Cyclin dependent kinase 4 | Q5198250 |
| | breast neoplasm | Q23929670 |
| | Cyclin-dependent kinase 6 | Q24775310 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 637-649 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Current Cancer Drug Targets | Q332547 |
| P1476 | title | HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles | |
| P478 | volume | 17 | |